LIXTE Biotechnology's LB-100 Advances Cancer Treatment in Evolving Landscape

LIXTE Biotechnology is developing LB-100, an experimental compound designed to enhance the effectiveness of cancer therapies by targeting biological mechanisms that influence immune recognition and tumor sensitivity to treatment. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. This strategy aligns with the evolving oncology landscape, where experts are exploring how different treatment approaches can work together to improve outcomes for cancer patients.